[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"platelet-thrombus\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:platelet-thrombus":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,52],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":24,"studyType":25,"phases":4,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100305417","dynamics-of-platelet-activation-in-patients-with-ventricular-assist-device-vad-100305417",false,"NCT03255928","Dynamics of Platelet Activation in Patients With Ventricular Assist Device (VAD)","Analysis of the Platelet Activity State in Patients Implanted With Ventricular Assist Device (VAD)","PASVAD","Inclusion Criteria:\n\n* All consenting patients candidates for short-term (Impella, ECMO) or durable (LVAD) mechanical circulatory support device implantation\n* All consenting patients that are implanted with short-term (Impella, ECMO) or durable (LVAD) mechanical circulatory support device\n\nExclusion Criteria:\n\n\\- Patients \\\u003C 18-years old",true,"ALL","18 Years","75 Years",{"count":22,"type":23},60,"ESTIMATED","2 Years","OBSERVATIONAL","Consenting patients with end-stage heart failure that are implanted with\u002Fcandidates for implant of a short-term\u002Fdurable mechanical circulatory support device (e.g.: percutaneous microaxial pumps (Impella), extracorporeal membrane oxygenator (ECMO), Ventricular Assist Device (VAD) will be enrolled in the study.\n\nAim of the study is to evaluate the patients' haemostatic and coagulation profile, how it interacts with the support device as well as the effect of antithrombotic drugs. From these data, it will be possible to derive the mechanisms triggering post-implant thromboembolic\u002Fhemorrhagic complications and to identify potential therapeutic targets.",[28,29,30,31,32],"Thrombosis","Blood Coagulation Disorder","Platelet Thrombus","Platelet Dysfunction Due to Aspirin","Failure;Ventricular",[34,35,28,36,37,38],"Platelet activation","Ventricular Assist Device","Bleeding","Antithrombotic Pharmacological Therapy","Mechanical Circulatory Support","RECRUITING","2025-05-12",{"date":42,"type":43},"2025-05-15","ACTUAL",{"date":45,"type":43},"2017-06-29",{"date":47,"type":23},"2026-12-31",{"name":49,"class":50},"Scientific Institute San Raffaele","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":17,"sex":18,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":63,"conditions":64,"keywords":65,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":51},"100539041","characterization-of-exosomes-platelets-released-100539041","NCT06298682","Characterization of Exosomes Platelets-released","EXOPLT","Inclusion Criteria:\n\n* subjects without known pathologies\n\nExclusion Criteria:\n\n* individuals with gastrointestinal diseases,\n* individuals with history of hepatic diseases,\n* individuals with history of urogenital diseases,\n* individuals with history of hematological diseases,\n* individuals with history of immunological diseases,\n* individuals with history of renal diseases,\n* individuals with history of metabolic diseases\n* individuals with history of respiratory diseases\n* individuals with history of cancer\n* individuals with history of cardiovascular disease\n* individuals having permanent organ damage\n* individuals with major trauma in the last 6 months prior to enrollment\n* individuals with surgery in the last 6 months prior to enrollment\n* individuals taking medication in the 15 days prior to enrolment.","20 Years","60 Years",{"count":62,"type":23},175,"Extracellular vesicles (EVs) play a key role in cell-to-cell communication. They are small vesicles that contain rich molecular cargo. Recently, they have been proposed as biomarkers for clinical diagnostics. EVs include three classes: small EVs (exosomes), large EVs (microparticles), and apoptotic bodies. Platelet-derived EVs (PEVs) are the most abundant class in human blood and can actively participate in numerous physiological and pathological processes. The information about the role of platelet exosomes in cardiovascular disease and the effect of antiplatelet agents on their release and content is very limited.",[30],[66],"exosomes, platelet activation, platelet inhibitors","2024-03-07",{"date":69,"type":43},"2024-03-12",{"date":71,"type":43},"2021-07-08",{"date":73,"type":23},"2027-07-07",{"name":75,"class":50},"Centro Cardiologico Monzino"]